Daniel Lyons, Ph.D., CFA
Daniel Lyons is a Portfolio Manager and Research Analyst at Janus Henderson Investors responsible for co-managing the Biotechnology strategy since 2018. Dr. Lyons started consulting for Janus in 1997 and joined the Health Care Sector Research Team full time in 2000. As a research analyst, he focuses on the biotechnology and life science tools sectors.
Dr. Lyons received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a Ph.D. from Stanford University’s program in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 21 years of financial industry experience.
Articles Written
COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks
Making sense of the latest developments around COVID-19 variants and what investors should consider now.
COVID-19 Vaccine Beats Expectations
How a novel vaccine candidate from Pfizer and BioNTech could shape the trajectory of the global pandemic.
What a Return to “Normal” Could Mean for Equities
In our ongoing video series on COVID-19, a discussion of the pandemic’s trajectory, vaccine development and investment considerations post-crisis.
COVID-19: Understanding the Science & Investment Implications (Part IV)
A new video series from our health care team offers unique insight into the scientific and investment implications of the COVID-19 crisis.